Pfizer Gross Profit vs. Number Of Shares Shorted

PFE Stock  USD 25.23  0.33  1.29%   
Considering Pfizer's profitability and operating efficiency indicators, Pfizer Inc may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Pfizer's ability to earn profits and add value for shareholders.
 
Gross Profit  
First Reported
1985-09-30
Previous Quarter
8.2 B
Current Value
11.1 B
Quarterly Volatility
4.6 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Pfizer's Days Sales Outstanding is projected to drop based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.33, whereas EV To Sales is forecasted to decline to 3.66. At present, Pfizer's Income Quality is projected to increase slightly based on the last few years of reporting. The current year's Net Income Per E B T is expected to grow to 2.10, whereas Operating Income is forecasted to decline to about 3.2 B.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.4925
Significantly Up
Slightly volatile
Net Profit Margin0.03440.0362
Notably Down
Pretty Stable
Operating Profit Margin0.05460.0574
Notably Down
Slightly volatile
Pretax Profit Margin0.01720.0181
Notably Down
Pretty Stable
Return On Assets0.00890.0094
Notably Down
Pretty Stable
Return On Equity0.02260.0238
Notably Down
Pretty Stable
For Pfizer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pfizer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pfizer Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pfizer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pfizer Inc over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.98)
Dividend Share
1.67
Earnings Share
0.74
Revenue Per Share
10.493
Quarterly Revenue Growth
0.312
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pfizer Inc Number Of Shares Shorted vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth.
Pfizer Inc is considered to be number one stock in gross profit category among its peers. It also is considered to be number one stock in number of shares shorted category among its peers . The ratio of Gross Profit to Number Of Shares Shorted for Pfizer Inc is about  700.57 . At present, Pfizer's Gross Profit is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pfizer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Pfizer Number Of Shares Shorted vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Pfizer

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
66.23 B
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Pfizer

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
94.54 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Pfizer Number Of Shares Shorted Comparison

Pfizer is currently under evaluation in number of shares shorted category among its peers.

Pfizer Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pfizer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pfizer will eventually generate negative long term returns. The profitability progress is the general direction of Pfizer's change in net profit over the period of time. It can combine multiple indicators of Pfizer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-8 B-7.6 B
Operating Income3.4 B3.2 B
Income Before Tax1.1 BB
Total Other Income Expense Net-2.3 B-2.4 B
Net Income2.2 B2.1 B
Income Tax Expense-1.1 B-1.1 B
Net Income Applicable To Common Shares36.1 B37.9 B
Net Income From Continuing Ops2.2 B2.1 B
Non Operating Income Net Other-249.6 M-262 M
Interest Income1.6 B924.4 M
Net Interest Income-585 M-614.2 M
Change To Netincome-2.5 B-2.3 B
Net Income Per Share 0.38  0.36 
Income Quality 4.01  4.21 
Net Income Per E B T 2.00  2.10 

Pfizer Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pfizer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pfizer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pfizer's important profitability drivers and their relationship over time.

Use Pfizer in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.

Pfizer Pair Trading

Pfizer Inc Pair Trading Analysis

The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pfizer position

In addition to having Pfizer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Strategy ETFs Thematic Idea Now

Strategy ETFs
Strategy ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1282 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
To fully project Pfizer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pfizer Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pfizer's income statement, its balance sheet, and the statement of cash flows.
Potential Pfizer investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pfizer investors may work on each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.